Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04901897 · ClinicalTrials.gov registry record · NA

Product Performance of a New Silicone Hydrogel Contact Lens

A NA study of Myopia, sponsored by Bausch & Lomb Incorporated.

Completed
Registry status
NA
Development phase
805
Enrollment target
20
Study locations

NCT04901897: Completed NA study of Myopia, sponsored by Bausch & Lomb Incorporated.

NCT04901897 is a NA study of Myopia that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 805 participants, above the 259-participant average among 90 other Myopia trials with a reported enrollment target (211% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04901897, a NA study of Myopia, has completed, sponsored by Bausch & Lomb Incorporated.

COMPLETED
Registry status
NA
Development phase
805 participants
Enrollment target
20
Study locations

Study Summary

The objective of this study is to evaluate the product performance of kalifilcon A, compared to the Johnson \& Johnson Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens and Alcon DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses when worn by current soft contact lens wearers on a daily disposable wear basis.

Primary Outcome

logMAR is the logarithm of the minim angle of resolution

Conditions Studied

Interventions

  • DEVICE senofilcon A
  • DEVICE delefilcon A
  • DEVICE kalifilcon A

Study Locations (20)

California

  • Bausch Site 406 - Azusa
  • Bausch Site 430 - Los Angeles
  • Bausch Site 419 - San Diego
  • Bausch Site 435 - San Francisco
  • Bausch Site 432 - Sunnyvale
  • Bausch Site 409 - Torrance

Florida

  • Bausch Site 415 - Jacksonville
  • Bausch Site 434 - Jacksonville
  • Bausch Site 405 - Sarasota

Hawaii

  • Bausch Site 437 - Honolulu
  • Bausch Site 401 - ‘Aiea

Alabama

  • Bausch Site 433 - Birmingham

Arizona

  • Bausch Site 431 - Scottsdale

Colorado

  • Bausch Site 416 - Denver

Georgia

  • Bausch Site 412 - Decatur

Kansas

  • Bausch Site 414 - Leavenworth

Trial Details

FieldValue
Enrollment Target 805 participants
Start Date 2019-07-31
Est. Completion 2019-10-09
Phase NA
Bausch & Lomb Incorporated

174 total trials

What the finished NCT04901897 record still lists

NCT04901897 is an interventional study that assigns participants to a tested intervention. The registered 805 participants enrollment target is mid-sized for trials with a published cap, above the 259-participant average among 90 other Myopia trials with a reported enrollment target (211% higher).

The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 3 interventions - of which senofilcon A is the first listed.

NCT04901897 names 20 study sites across 12 states, led by California, Florida, Hawaii.

Frequently Asked Questions

What is clinical trial NCT04901897 about?

NCT04901897 is a clinical study titled "Product Performance of a New Silicone Hydrogel Contact Lens". The objective of this study is to evaluate the product performance of kalifilcon A, compared to the Johnson \& Johnson Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens and Alcon DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses when worn by current soft c...

What is the current status of trial NCT04901897?

This trial is currently completed. It is a NA study. The enrollment target is 805 participants. The study started on 2019-07-31. Estimated completion is 2019-10-09.

What conditions does trial NCT04901897 study?

This clinical trial studies the following conditions: Myopia.

What interventions are being tested in trial NCT04901897?

The interventions under investigation include: senofilcon A (DEVICE), delefilcon A (DEVICE), kalifilcon A (DEVICE).

Who is sponsoring clinical trial NCT04901897?

This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04901897 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04901897's enrollment target sits among peer trials

805 6th of 90 higher than 85 of 90 other Myopia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04613596 · 806 participants · Phase 2

    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • NCT06065098 · 806 participants · NA

    Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health

  • NCT04423211 · 804 participants · Phase 3

    Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

  • NCT06522022 · 804 participants · NA

    PTSD Screening in Pregnant Black Women

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04901897, the US trial registry maintained by the National Library of Medicine. NCT04901897 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.